Evidence map›Paper›PMID 30254251›Full record

ReviewNature reviews. Immunology2018

Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer.

Simon A Jones, Brendan J Jenkins

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04494724 (A Phase 2 Trial to Evaluate the Safety and Tolerability of Clazakizumab® [Anti-Interleukin), which is not on this map. Cited by 654 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
654citing papers in PubMed, 4 pooled it
32.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04494724 phase2recruitingnot on this mapstarted 2020, after this paper: background citation

A Phase 2 Trial to Evaluate the Safety and Tolerability of Clazakizumab® [Anti-Interleukin (IL)-6 Monoclonal] Compared to Placebo for the Treatment of COVID-19 Infection

TypeinterventionalSponsorThe Methodist Hospital Research InstituteRan2020 to 2021Enrolled60ConditionsCOVID-19 InfectionArmsClazakizumab, Placebo
3 · Its place in the literature

Who cites it

654 citing papers in PubMed, 4 syntheses or guidelines pooled it, 1,057 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

594 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Simon A JonesDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, Wales, UK. JonesSA@cardiff.ac.uk.
Brendan J JenkinsCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia. brendan.jenkins@hudson.org.au.
Cardiff University · GBHudson Institute of Medical Research · AU

Funding

Versus Arthritis 20770
6 · The paper itself

Abstract

The IL-6 family of cytokines consists of IL-6, IL-11, IL-27, IL-31, oncostatin M (OSM), leukaemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), cardiotrophin 1 (CT-1) and cardiotrophin-like cytokine factor 1 (CLCF1). Membership of this cytokine family is defined by usage of common β-receptor signalling subunits, which activate various intracellular signalling pathways. Each IL-6 family member elicits responses essential to the physiological control of immune homeostasis, haematopoiesis, inflammation, development and metabolism. Accordingly, distortion of these cytokine activities often promotes chronic disease and cancer; the pathological importance of this is exemplified by the successful treatment of certain autoimmune conditions with drugs that target the IL-6 pathway. Here, we discuss the emerging roles for IL-6 family members in infection, chronic inflammation, autoimmunity and cancer and review therapeutic strategies designed to manipulate these cytokines in disease.

Indexed as

Adaptive ImmunityAutoimmune DiseasesCytokine Receptor gp130HumansImmunity, InnateInflammationInterleukin-6NeoplasmsSignal TransductionCytokine Receptor gp130IL6 protein, humanIL6ST protein, humanInterleukin-6

Identifiers

PMID30254251
OpenAlexW2893631054

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.